Last reviewed · How we verify
Saline placebo for pembrolizumab
Saline placebo for pembrolizumab is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Control arm in pembrolizumab clinical trials (Phase 3).
Saline placebo is an inert control substance with no active pharmacological mechanism.
Saline placebo is an inert control substance with no active pharmacological mechanism. Used for Control arm in pembrolizumab clinical trials (Phase 3).
At a glance
| Generic name | Saline placebo for pembrolizumab |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Saline placebo consists of sterile sodium chloride solution and serves as a negative control in clinical trials to establish the efficacy of the active comparator (pembrolizumab). It has no direct mechanism of action on any molecular target or disease pathway.
Approved indications
- Control arm in pembrolizumab clinical trials (Phase 3)
Common side effects
- Injection site reactions
- No expected pharmacological adverse events
Key clinical trials
- EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma (PHASE3)
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (PHASE3)
- Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saline placebo for pembrolizumab CI brief — competitive landscape report
- Saline placebo for pembrolizumab updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Saline placebo for pembrolizumab
What is Saline placebo for pembrolizumab?
How does Saline placebo for pembrolizumab work?
What is Saline placebo for pembrolizumab used for?
Who makes Saline placebo for pembrolizumab?
What development phase is Saline placebo for pembrolizumab in?
What are the side effects of Saline placebo for pembrolizumab?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Control arm in pembrolizumab clinical trials (Phase 3)
- Compare: Saline placebo for pembrolizumab vs similar drugs
- Pricing: Saline placebo for pembrolizumab cost, discount & access